Hanmi Pharmaceutical Company Limited
Clinical trials sponsored by Hanmi Pharmaceutical Company Limited, explained in plain language.
A South Korean pharmaceutical company developing drugs and biologics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug HM15275 enters Mid-Stage trial Results expected Jan 2027 (estimated)
- New obesity drug HM17321 enters first human safety trials Results expected Mar 2027 (estimated)
- New drug combo aims to shrink Hard-to-Treat tumors Results expected Aug 2027 (estimated)
-
New weekly shot shows promise for rare low blood sugar disorder
Disease control OngoingThis study tests a new medicine called HM15136 for people aged 2 and older with congenital hyperinsulinism (CHI) who still have low blood sugar despite standard treatments. The medicine is given as a weekly shot for 8 weeks. The goal is to see if it is safe and helps control bloo…
Phase 2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a dual protein blocker shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing an experimental drug called HM97662 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking two proteins, EZH1 and EZH2, which are thought to help tumors grow. The study aims t…
Phase 1 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New obesity drug HM15275 enters Mid-Stage trial
Disease control OngoingThis phase 2 study tests an experimental drug called HM15275 for weight loss in 267 adults who are obese or overweight but do not have diabetes. Participants receive either the drug or a placebo as a weekly injection for 36 weeks. The main goal is to see how much body weight chan…
Phase 2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC